NRC FORM 374 (7-94) U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 7

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letter dated February 26, 1996
1. **Charleston Radiation Therapy Consultants, LLC also d/b/a Charleston Brachytherapy Services, LLC**	3. License Number 47-15717-03 is amended in its entirety to read as follows:
2. Medical Staff Office Building 3100 MacCorkle Avenue, S.E., Suite B1 Charleston, West Virginia 25304	4. Expiration Date **January 31, 2006 (extended)**
	5. Docket or Reference No. 030-28869

6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License
A. Any byproduct material identified in 10 CFR 35.400	A. Any sealed brachytherapy source identified in 10 CFR 35.400 and registered pursuant to 10 CFR 32.210	A. 111 gigabecquerel (3 curies)
B. Strontium 90	B. Sealed source registered pursuant to 10 CFR 32.210 and contained in Nuclear Associates Model PTW-09 calibrator	B. 37 gigabecquerel (1 millicurie)
C.(1) Iridium 192	C.(1) Sealed sources (Byk-Mallinckrodt Model CIL B.V.), or	C.(1) Two sources, not to exceed 814 gigabecquerel (22 curies) [See item 9.C (1)], or
(2) Iridium 192	(2) Sealed sources (RTS models 721 or 724 or Mallinckrodt Model GM 212.03-000)	(2) Two sources, not to exceed 740 gigabecquerel (20 curies total) [see Item 9.C.(2)]
D. Uranium 238	D. Depleted uranium shielding	D. 14 kilograms

150034

9. Authorized Use:

A. For storage, packaging and transfer to and from the Charleston Area Medical Center (License No. 47-15473-01.)

B. For use in the calibration and testing of radiation detection equipment.

0/1

ML20

9. Authorized Use (cont.)

C.(1) One source not to exceed 10 curies in a compatible Nucletron-Oldelft Corporation Model Micro Selectron-HDR (096.999) remote afterloading brachytherapy irradiator for treatment of cancer patients, and one source not to exceed 12 curies for storage in its shipping container for decay to 10 curies at the licensee's facility, incident to source replacement, or

(2) One source not to exceed 12 curies in a compatible Isotopen-Technik Model GammaMed 12 i remote afterloading brachytherapy irradiator for treatment of cancer patients, and one source not to exceed 12 curies for storage in its shipping container, incident to source replacement.

D. Depleted uranium metal contained in Isotopen-Technik Model GammaMed 12 i for shielding.

CONDITIONS

10. Licensed material shall be used only at the licensee's facility located at 3100 MacCorkle Avenue, S.E., Medical Staff Office Building, Suite B1, Charleston, West Virginia except that licensed material identified in Items 6.C, 7.C, 8.C, and 9.C or 6.D, 7.D, 8.D and 9.D shall be used only in the licensee's teletherapy exposure room located at 3100 MacCorkle Avenue, S.E., Medical Staff Office Building, Suite B1, Charleston, West Virginia

11. A. Radiation Safety Officer (RSO) for this license is Isaac Warren Bryant or in his absence, Paula M. Prokorym, alternate Radiation Safety Officer.

B. Medical Physicist for this license is Isaac Warren Bryant or in his absence, David M. Nelson, Staff Medical Physicist.

12. Licensed material listed in Item 6 above shall be used only by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users	Material and Use
A.	Kshama S. Jawalekar, M.D. for medical use of iridium 192 in an HDR remote afterloading brachytherapy unit (see item 6.C) for interstitial and intracavitary treatment of cancer.
B.	Lewis Whaley, D.O. for medical use of iridium 192 in an HDR remote afterloading brachytherapy unit (see item 6.C) for interstitial and intracavitary treatment of cancer.
C.	Michael Harmon, M.D. for medical use of iridium 192 in an HDR remote afterloading brachytherapy unit (see item 6.C) for interstitial and intracavitary treatment of cancer.
D.	Isaac Warren Bryant, M.S. for radiation safety supervision and medical physics duties associated with the receipt, storage, handling, use, and/or transfer of licensed material identified in items 6, 7, 8 and 9 of this license.

13. Sealed sources containing licensed material shall not be opened by the licensee.

14. The licensee may transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material".

CONDITIONS

Continued

15. The licensee shall maintain records of information important to safe and effective decommissioning at the address specified in Condition 10. above pursuant to the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.

16. Prior to initiation of a treatment program, and subsequent to each source exchange, using the HDR remote afterloading brachytherapy devices, radiation surveys and tests shall be performed in accordance with the following:

A. A radiation survey shall be made of:

1. The afterloader source housing, with the source in the shielded position. The maximum radiation levels at 10 centimeters from the nearest accessible surface of the main source safe shall not exceed 1 milliroentgen per hour.

2. All areas adjacent to the treatment room with the source in the "irradiation" position. The survey shall clearly establish:

(a) That radiation levels in restricted areas are not likely to cause personnel exposure in excess of the limits specified in 10 CFR 20.1201.

(b) That radiation levels in unrestricted areas do not exceed the limits specified in 10 CFR 20.1301.

17. Following any use of the HDR device identified in this license, the licensee shall, immediately after retracting the source from the patient, perform a radiation survey of the patient and the remote afterloading device with a portable radiation detection survey instrument to confirm that the source has been removed from the patient and reshielded in the HDR. Records of the survey shall be maintained in accordance with 10 CFR 35.404(b).

18. In lieu of the source inventory required in 10 CFR 35.406, the licensee shall:

A. Promptly determine that all sources have returned to the safe, shielded position at the conclusion of each remote afterloading brachytherapy procedure.

B. Promptly make a survey of the area of use to confirm that no sources have been misplaced.

C. Make a record of the survey including the survey instrument used, dose rate expressed in mrem/hr (microSieverts/hr), time, date and name of the individual making the survey.

D. Retain the record of the survey in lieu of the record required in 10 CFR 35.406(d).

19. The following shall be performed only by manufacturer's representatives or persons specifically authorized by the Commission or an Agreement State to perform such services:

A. Installation and replacement of sources contained in the HDR remote afterloading brachytherapy irradiator shall be performed only by persons specifically authorized by the Commission or an Agreement State to perform such services.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number 47-15717-03

Docket or Reference Number 030-28869

Amendment No. 7

CONDITIONS

19. HDR maintenance (cont.)

B. Any maintenance or repair operations on the HDR remote afterloading brachytherapy device involving work on the source safe, the source drive unit, or other mechanism that could expose the source, reduce the shielding around the source, or compromise the safety of the unit and result in increased radiation levels.

20. A. Access to the rooms housing the HDR afterloading brachytherapy device shall be controlled by a door at each entrance.

B. The entrance to the irradiation room shall be equipped with an electrical interlock system that will cause the source to return to the shielded position immediately upon opening of the entrance door. The interlock system shall be connected in such a manner that the source cannot be placed in the irradiation position until the entrance door is closed and the source "on-off" control is reset at the control panel.

C. Electrical interlocks on the entrance door to the irradiator room shall be tested for proper operation at least once each day of use. Records of tests results shall be maintained for inspection by the Commission for a period of three years.

D. In the event of malfunction of the door interlock, the remote afterloading brachytherapy device shall be locked in the "off" position and not used, except as may be necessary for repair or replacement of the interlock system, until the interlock system is shown to be functioning properly.

21. At intervals not to exceed one year, the licensee shall ensure that the HDR device is fully inspected and serviced for proper functioning of the source exposure mechanism. Inspection and servicing shall be in accordance with the device manufacturer's written instructions and records shall be maintained and shall include the name and license number of the individual performing the service, a description of the service performed, a list of components replaced and the signature of the individual performing the service.

22. At least two individuals designated in accordance with Conditions 11 and 12 and consisting of an authorized user for the HDR brachytherapy device, and either the Medical Physicist or the Radiation Safety Officer shall be present (i.e., within audible range of normal human speech) during every patient treatment using the HDR device.

23. A. The licensee may not possess and use materials authorized in Items 6.C.,D, 7C.,D, and 8.C.D, until: 1) the licensee has constructed facilities and obtained the equipment described in the application and supporting documentation; and 2) the U.S. Nuclear Regulatory Commission, Region II, ATTN: Chief, Materials Licensing Branch 2, 101 Marietta Street NW, Suite 2900, Atlanta, GA 30323-0199, has been notified in writing that activities authorized by the license will be initiated.

B. In accordance with the requirements set forth in 10 CFR 30.36(b), the licensee shall promptly notify the Nuclear Regulatory Commission, in writing of a decision not to complete the facility, acquire equipment, or possess and use authorized material.

License Number 47-15717-03

Docket or Reference Number 030-28869

MATERIALS LICENSE
SUPPLEMENTARY SHEET

Amendment No. 7

CONDITIONS

24. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application received August 3, 1995 [This application contains request for renewal of License and amendment to include an HDR remote afterloading brachytherapy unit.] {This application was prepared and signed by Warren Bryant, Physicist and RSO.}

B. Letters dated October 10, 1995 [This letter contains clarifying information about the HDR portion of the application.]

C. Letter dated October 26, 1995 [This letter contains additional information about the licensee's radiation safety program for storage and handling of sealed brachytherapy sources for transfer to another licensee.]

D. Letter dated December 8, 1995 [This letter contains information about the training and experience of the alternate Radiation Safety Officer and the alternate Medical Physicist.]

E. Letter dated January 29, 1996 (FAX) [This correspondence contains clarifying information about the licensee's Standard Operating Procedures applicable to HDR brachytherapy Quality Management Program.]

F. Letter dated February 23, 1996 [This letter adds a subsidiary corporation to the name of the licensee]

G. Letter dated April 24, 1996 [This letter states the controlling interests and all current license conditions will be met]

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

DAVID J. COLLINS

DATE JUN 17 1996 BY David J. Collins

Region II, Division of Nuclear Materials Safety
101 Marietta Street, N.W., Suite 2900
Atlanta, Georgia 30323-0199

N:\MLICENSE\47-15717.A07

6/17/96

UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION II
101 MARIETTA STREET, N.W., SUITE 2900
ATLANTA, GEORGIA 30323-0199

JUN 17 1996

INFORMATION FOR NRC MATERIAL LICENSEES

Please find enclosed:
_____ Your NRC material license
__✓__ Amendment to your NRC material license
_____ Amendment renewing your NRC material license
_____ Amendment terminating your NRC material license
_____ Notice for Radiographer Quality Assurance Approval Program

Please review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify this office (ATTN: Ms. Diane Heim at (404) 331-4673) so that we can provide appropriate corrections and answers.

Please be advised that your license expires at the end of the day in the month and year stated in the license. Unless your license has been terminated, you must conduct your program involving byproduct materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR 19, "Notice, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.

2. Not possess and use materials authorized in Items 6, 7, and 8, on the license until:

   a. you have constructed the facilities and obtained the equipment described in the license application and supporting documentation; and

   b. you have notified the U. S. Nuclear Regulatory Commission, Region II, ATTN: Materials Licensing\Inspection Branch, in writing, that activities authorized by the license will be initiate

   c. you have submitted & certified implementation of a Quality Management Program (10 CFR 35.32) for radiotherapy, or for administering >30 uCi of I-125 or I-131.

3. Notify NRC, in writing, within 30 days:

   a. when an authorized user, Radiation Safety Officer, or Teletherapy Physicist permanently discontinues performance of duties under the license or has a name change; or

   b. when the licensee's mailing address changes (no fee is required if the location of byproduct material remains the same).

4. In accordance with 10 CFR 30.36(b) and/or license condition, notify NRC, promptly, in writing, and request termination of the license:

   a. when you decide to terminate all activities involving materials authorized under the license; or

   b. if you decide not to complete the facility, acquire equipment, or possess and use authorized material.

5. Request and obtain a license amendment before you:

   a. receive or use byproduct material for a clinical procedure permitted under Part 35 but not permitted by your license issued pursuant to this part.

   b. permit anyone, not authorized under 10 CFR 35, Subpart J, to work as an authorized user under a license for medical use of byproduct material.

   c. permit anyone, not authorized under 10 CFR 35, Subpart J, to work as a Radiation Safety Officer, Teletherapy Physicist, or Nuclear Pharmacist, under a license for medical use of byproduct material.

   d. order byproduct material in excess of the amount, or a different radionuclide or form, other than authorized on the license;

   e. add or change the areas of use or address (or addresses) of use identified in the license application or on the license; or

   f. change ownership of your organization.

6. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date of your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of byproduct material after your license expires is a violation of NRC regulations. Transfer of licensed materials must be consistent with 10 CFR 30.41, 40.51 or 70.42, as applicable. A license will not normally be renewed, except on a case-by-case basis, in instances where licensed material has never been possessed or used.

In addition, please note that NRC Form 313 requires the applicant, by his/her signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant.

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a Notice of Violation, or imposition of a Civil Penalty, or an order suspending, modifying or revoking your license as specified in the "General Statement of Policy and Procedures for NRC Enforcement Actions," NUREG-1600, (7/95). Since serious consequences to employees and the public can result from failure to comply with NRC requirements, prompt and vigorous enforcement action will be taken against those who do not achieve the necessary attention to detail and standard of compliance expected of licensees.

Thank you for your cooperation.

Enclosures:
1. NRC License
2. Category Marked Below for:
   [ ] New licenses: NUREG-1600 (7/95); 19; 20; 30; 40 or 70, as appropriate; 71; 170; NRC Form 3; Agreement State list; and NRC Form 313.
   [ ] New radiography licenses: Parts 34; 150.
   [ ] New medical and teletherapy licenses: Part 35.
   [ ] Amendments and renewals: NRC Form 313.

NRC FORM 577 (1-95) U.S. NUCLEAR REGULATORY COMMISSION

LICENSE FEE REQUIREMENTS

LICENSE FEE AND DEBT COLLECTION BRANCH
DIVISION OF ACCOUNTING AND FINANCE
OFFICE OF THE CONTROLLER
U.S. NUCLEAR REGULATORY COMMISSION
WASHINGTON, DC 20555-0001

Charleston Radiation Therapy
Attn; Warren Bryant
Radiation Safety Officer
3100 MacCorkle Avenue, SE, Suite B1
Charleston, WV 25304

TYPE OF ACTION

- ☐ NEW LICENSE
- ☐ RENEWAL OF LICENSE
- ☒ AMENDMENT TO LICENSE

REQUESTED DATE: 4-24-96

LICENSE NUMBER: 47-15717-03

CONTROL NUMBER: 257049 Attn: Rita Messier, LFARB, T9E10

I. APPLICATION FEE DUE

Your request for a licensing action is subject to the fee(s) in the category(ies) noted below in accordance with Section 170.31 of the enclosed Federal Register notice. Payment of the fee is required prior to the issuance of the license, renewal, or amendment.

FEE CATEGORY	APPLICATION	RENEWAL	AMENDMENT
7C	$	$	$ 430.00
	$	$	$
	$	$	$
	$	$	$
	$	$	$
	$	$	$
	$	$	$
	$	$	$
	$	$	$

FEE(s) DUE	$ 430.00
PAYMENT RECEIVED	$
AMOUNT DUE	$ 430.00

☒ Your request was received without the prescribed application fee.

☐ We received your Check No. _____ in the amount of $ _____. Payment of the additional fee noted above is required.

☐ Your request will increase the scope of your license program. Therefore, your request is subject to the application fee(s) noted above. Refer to Section 170.31 and Footnote 1(d)(2).

☐ Your license expired prior to the receipt of your application for renewal. Therefore, your request is subject to the application fee(s) noted above. Refer to Section 170.31 and Footnote 1(a).

MAKE PAYMENT OF THE FEE(S) TO THE U.S. NUCLEAR REGULATORY COMMISSION AND MAIL THE PAYMENT TO THE ADDRESS LISTED AT THE TOP OF THIS FORM. IF WE DO NOT RECEIVE A REPLY FROM YOU WITHIN 30 CALENDAR DAYS FROM THE DATE LISTED BELOW, WE SHALL ASSUME THAT YOU DO NOT WISH TO PURSUE YOUR APPLICATION AND WILL VOID THIS ACTION.

II. FEE NOT REQUIRED

☐ Enclosed is Check No. _____ which accompanied your request. The fee is not required because:

- ☐ We received your Check No. _____ in payment of the fee.
- ☐ The Licensing staff has informed us that your request is to be considered as a continuation of your request dated _____, Control No. _____.
- ☐ Your request was combined, prior to review, with your _____ request, Control No. _____.

III. CHECK RETURNED

☐ Enclosed is Check No. _____ which was returned to us by the bank for:

- ☐ INSUFFICIENT FUNDS
- ☐ ACCOUNT CLOSED
- ☐ OTHER

MAIL THE REPLACEMENT CHECK TO THE ADDRESS LISTED AT THE TOP OF THIS FORM AND REFERENCE THE ABOVE CONTROL NUMBER.

IV. LICENSE ISSUED WITHOUT THE REQUIRED FEE

☐ License No. _____, Amendment No. _____, issued on _____ was issued without the required fee being collected. The fee required is noted in Section I of this form.

☐ The scope of your licensed program was increased. Therefore, your request is subject to the application fee(s) noted in Section 1 of this form. Refer to Section 170.31 and Footnote 1(d)(2).

☐ Because of the urgency of your request, the license was issued without remittance of the prescribed fee noted in Section 1 of this form.

SIGNATURE -- LICENSE FEE ANALYST			Distribution:	DATE
Rita Messier	LFDCB REMessier 5/7/96	LFDCB	X/DAF/BF CRCB RLF (2) Pending Fee File Region II OC/DAF/BF-CLF 3.2.7	5-7-96

NRC FORM 577 (1-95)

This form was electronically produced by Elite Federal Forms, Inc

L. Heim

April 15, 1996

Kanawha Radiological Physics, Inc.
ATTN: Mr. Warren Bryant
RSO for CRTC
Suite B1, 3100 MacCorkle Ave., SE
Charleston, WV 24304

Dear Mr. Bryant:

In regard to your letter dated February 23, 1996, enclosed you will find a series of questions to be answered in order for us to determine if the referenced license can be amended as you requested. I believe the determining factor would be if the "controlling interests" of the two firms will remain identical, we would be able to add a "dba" line to the license.

Upon receipt of your response, we will make this determination and contact you in regard to this matter. If you have any further questions regarding this matter, please contact me at 404-331-5571. We apologize for the delay in responding to your request.

Sincerely,

/s/

John P. Potter, Chief
Nuclear Materials Branch 2

Enclosure: As stated

Distribution w/encl:
PUBLIC
RII Docket Files, DNMS

OFFICE	DNMS:RII											
SIGNATURE												
NAME	JPPotter											
DATE	04 /	/ 96	04 /	/ 96	04 /	/ 96	04 /	/ 96	04 /	/ 96	04 /	/ 96
COPY?	YES	NO	YES	NO	YES	NO	YES	NO	YES	NO	YES	NO

OFFICIAL RECORD COPY DOCUMENT NAME: G:\DRSS\NMLS\DEFLTR\KANAWHA.LTR

INFORMATION NEEDED FOR CHANGE OF OWNERSHIP APPLICATION

The applicant should provide the following information concerning changes of ownership or control by the applicant (transferor and/or transferee, as appropriate):

1. The new name of the licensed organization. If there is no change, the licensee should so state.

2. The new licensee contact and telephone number(s) to facilitate communications.

3. Any changes in personnel having control over licensed activities (e.g., officers of a corporation) and any changes in personnel named in the license such as radiation safety officer, authorized users, or any other persons identified in previous license applications as responsible for radiation safety or use of licensed material. The licensee should include information concerning the qualifications, training, and responsibilities of new individuals.

4. An indication of whether the transferor will remain in non-licensed business without the license.

5. A complete, clear description of the transaction, including any transfer of stocks or assets, mergers, etc., so that legal counsel is able, when necessary, to differentiate between name changes and changes of ownership.

6. A complete description of any planned changes in organization, location, facility, equipment, or procedures (i.e., changes in operating or emergency procedures).

7. A detailed description of any changes in the use, possession, location or storage of the licensed materials.

8. Any changes in organization, location, facilities, equipment, procedures, or personnel that would require a license amendment even without the change of ownership.

9. An indication of whether all surveillance items and records (e.g., calibrations, leak tests, surveys, inventories, and accountability requirements) will be current at the time of transfer. A description of the status of all surveillance requirements and records should also be provided.

10. Confirmation that all records concerning the safe and effective decommissioning of the facility, pursuant to 10 CFR 30.35(g), 40.36(f), 70.25(g), and 72.30(d); public dose; and waste disposal by release to sewers, incineration, radioactive material spills, and on-site burials, have been transferred to the new licensee, if licensed activities will continue at the same location, or to the NRC for license terminations.

11. A description of the status of the facility. Specifically, the presence or absence of contamination should be documented. If contamination is present, will decontamination occur before transfer? If not, does the successor company agree to assume full liability for the decontamination of the facility or site?

12. A description of any decontamination plans, including financial assurance arrangements of the transferee, as specified in 10 CFR 30.35, 40.36, and 70.25. This should include information about how the transferee and transferor propose to divide the transferor's assets, and responsibility for any cleanup needed at the time of transfer.

13. Confirmation that the transferee agrees to abide by all commitments and representations previously made to NRC by the transferor. These include, but are not limited to: maintaining decommissioning records required by 10 CFR 30.35(g); implementing decontamination activities and decommissioning of the site; and completing corrective actions for open inspection items and enforcement actions.

    With regard to contamination of facilities and equipment, the transferee should confirm, in writing, that it accepts full liability for the site, and should provide evidence of adequate resources to fund decommissioning; or the transferor should provide a commitment to decontaminate the facility before change of control or ownership.

    With regard to open inspection items, etc., the transferee should confirm, in writing, that it accepts full responsibility for open inspection items and/or any resulting enforcement actions; or the transferee proposes alternative measures for meeting the requirements; or the transferor provides a commitment to close out all such actions with NRC before license transfer.

14. Documentation that the transferor and transferee agree to the change in ownership or control of the licensed material and activity, and the conditions of transfer; and the transferee is made aware of all open inspection items and its responsibility for possible resulting enforcement actions.

15. A commitment by the transferee to abide by all constraints, conditions, requirements, representations, and commitments identified in the existing license. If not, the transferee must provide a description of its program, to ensure compliance with the license and regulations.

BETWEEN:

License Fee Management Branch, ARM
and
Regional Licensing Sections

(FOR LFMS USE)
INFORMATION FROM LTS

Program Code: 02230
Status Code: 0
Fee Category: 7C
Exp. Date: 20060131
Fee Comments: _____
Decom Fin Assur Reqd: N

1996 MAY -7 AM 7:08

LICENSE FEE TRANSMITTAL

A. REGION II

1. APPLICATION ATTACHED
Applicant/Licensee: CHARLESTON RADIATION THERAPY
Received Date: 960430
Docket No: 3028869
Control No.: 257049
License No.: 47-15717-03
Action Type: Amendment

To add OBA Line

2. FEE ATTACHED
Amount: /
Check No.: /

3. COMMENTS

Signed Diane D. Herm
Date 4/30/96

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered N/A)

1. Fee Category and Amount: 7C #430

2. Correct Fee Paid. Application may be processed for:
Amendment ✓
Renewal _____
License _____

3. OTHER _____

Signed Rita Messier
Date 6/7/96

Log May I II
Remitter
Check No. 1268 #430
Amount
Fee Category 7C
Type of Fee Amd
Date Check Rec'd.
Date Completed 6/7/96
By: Rm

Kanawha Radiological Physics, Inc.
Suite B1, 3100 MacCorkle Ave., SE, Charleston, WV, 25304
304 345 0667

→ Diane – I think this is a Charles Radiation Therapy consultant with a name change only.

4/30/96

U.S. Nuclear Regulatory Commission
Region II
101 Marietta Street, N.W., Suite 2900
Atlanta, GA., 30323-0199

Atten: Mr. John Potter

24 April 1996

Reference: Your letter dated April 15, 1996

Dear Mr. Potter,

In response to your referenced letter;

1. the controlling interest of the two firms will remain the same
2. all current license conditions will remain intact

Based on the content of the information packet you sent, I believe that the above two statements preclude an item by item response to the query. Nonetheless, if you require additional information, please contact me directly. Thank you for your assistance.

Sincerely,

Warren Bryant
Warren Bryant
RSO for CRTC

cc M.B. Harmon, M.D.
File

257049

Kanawha Radiol[redacted]l Physics, Inc.
Suite B1, 3100 MacCorkle Ave., SE, Charleston, WV, 24304 304 345 0667

U.S. Nuclear Regulatory Commission
Region II
101 Marietta Street, N.W., Suite 2900
Atlanta, GA., 30323-0199

Atten: Mr. John Potter

23 February 1996

Subject: License # 47 15717 03 ... Charleston Radiation Therapy Consultants, LLC (CRTC)

Dear Mr. Potter,

The above referenced license has just recently been renewed and received by us for review. During the review process, I was informed by one of the authorized users that a new professional corporation is being established for the HDR practice. The name of the new corporation is Charleston Brachytherapy Services, Limited Liability Company (LLC).

In the interest of streamlining the cost of medical care and custodial duties associated with licence maintenance, is it possible to amend item 1. of our current materials license to read:

Charleston Radiation Therapy Consultants, also d.b.a. Charleston Brachytherapy Services, Limited Liability Company. If so, please amend our license to reflect this change.

Earl Wright is very familiar with this license. I have conferred with him regarding this matter and he recommended that we defer to your judgment. Contact me directly for any communications in this regard.

Sincerely,

Warren Bryant

Warren Bryant
RSO for CRTC

cc M.B. Harmon, M.D.
File